Summary

The point-of-care glucose testing market is expected to grow at a strong CAGR of around 4% during the forecast period. The adoption of point-of-care glucose testing is increasing at a rapid rate owing to several associated advantages, such as fast, easy, and mobile diagnosis and self-monitoring. These products facilitate diagnosis and monitoring for patients at hospitals, health assessment centers, clinics, and homes. Apart from this, the rising investment from pharmaceutical investment is also propelling the market growth. For instance, in August 2020, Precision Diabetes, Inc announced an exclusive agreement with DxGen Corp. to launch Epithod AutoDx, a fully automatic point-of-care (POC) analyzer that measures a comprehensive profile of diabetes tests. Further in June 2019, Abbott launched Afinion hemoglobin A1c (HbA1c) Dx test for use in diagnosing diabetes and monitoring blood glucose in point-of-care settings.

Reasons to buy this report:
• The study includes market sizing and forecasting analysis validated by authenticated key industry experts.
• The report presents a quick review of overall industry performance at one glance.
• The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolios, expansion strategies, and recent developments.
• Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.
• The study comprehensively covers the market across different segments.
• Deep dive regional level analysis of the industry.

Customization Options:
The global point-of-care glucose testing market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.
Some of the major players operating in the market include F. Hoffmann-La Roche Ltd; Abbott; Bayer AG; Nova Medical; ACON Laboratories, Inc.; Prodigy Diabetes Care, LLC; Trividia Health, Inc.; Nipro; EKF Diagnostics Holdings plc; and Platinum Equity Advisors, LLC. Several M&As along with partnerships have been undertaken by these players to facilitate customers with hi-tech and innovative products/technologies.

Insights Presented in the Report
“Amongst product, the freestyle lite segment to grow with high CAGR during the forecast period”
Based on product, the market is segmented into accu check aviva meter, onetouch verio flex, i-STAT, freestyle lite, Bayer contour blood glucose monitoring system, true metrix, accu-chek inform II, statStrip, and others. The freestyle lite segment is anticipated to grow with a significant CAGR period during the forecast period. FreeStyle Lite is offered by Abbott and is available in discreet size with an in-built portlight and backlight, which makes it user-friendly for patients with a busy lifestyle. The product is used for measuring blood sugar from samples collected from fingers, forearm, hand, upper arm, and thigh. It is recommended to use the FreeStyle Lite meter only with the FreeStyle control solution and testing strips as the usage of other control solutions and test strips can yield inaccurate results.

“Amongst end user, the hospitals category held a significant share of the market in 2021”
By end user, the market is categorized into hospitals, home settings, and others. The hospitals held the dominant share of the market in 2021 owing to the improving infrastructure and rising healthcare expenditure in hospitals. Moreover, the reliable data that point-of-care glucose testing provide practitioners in a fraction of seconds and the improvement in patients' quality of life have increased their adoption in the outpatient as well as inpatient hospital settings.
“APAC to grow with high CAGR during the forecast period”

APAC is expected to grow with the highest CAGR during the forecast period due to rising disposable income, the surge in the prevalence of diabetes, rising research and development activities, and increasing awareness among individuals. For instance, the International Diabetes Federation (IDF) estimates diabetes prevalence to be 11.6 per cent in Singapore, with the lifetime risk of developing diabetes at 1 in 3 among Singaporeans. Over 400,000 Singaporeans live with diabetes and existing health disparities need to be urgently addressed so they can get access to early diagnosis and therapy support, in order to better manage their chronic condition and prevent serious secondary complications.

ページTOPに戻る

Table of Contents